Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
385.05
Change Change %
-8.95 -2.27%

Updated:24 Sep, 2018, 15:56 PM IST

BSE
384.15
Change Change %
-10.85 -2.75%

Updated:24 Sep, 2018, 16:01 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Edelweiss
N/A
08-06-2017 Buy 531.35 600.00
N/A
Closed Long (1Y)
08-06-2018

Edelweiss maintains buy on Cadila Healthcare

Cadila Healthcare (CDH) has received approval for gLialda, the first and one of the most significant filings from Moraiya. Importantly, this development lends validation to CDH's other complex generic filings, especially gAsacol HD and others like gToprol XL, gPrevacid ODT and transdermals.Launches like these, we believe will lead to best-in-class US growth among peers, and drive around 44 per cent earnings CAGR for CDH over FY17-19E.

Top